Downstaging of hepatocellular carcinoma (HCC) is typically defined as the reduction in size or number of viable tumors through locoregional therapy (LRT), aiming to meet the established criteria for liver transplantation (LT). According to the Barcelona Clinic Liver Cancer (BCLC) staging system, a subgroup of patients with BCLC-B may benefit most from downstaging therapies. The United Network Organ Sharing downstaging protocol identifies potential candidates for downstaging by setting out ‘inclusion criteria’ and defining ‘successful downstaging.’ Additionally, the protocol considers factors related to tumor biology, such as an alphafetoprotein level <500 ng/mL after LRT. Reports indicate that successful downstaging rates following LRT are about 50%, with post- LT recurrence rates comparable to those of patients within the Milan criteria. A comprehensive multicenter US study on 10-year outcomes post-LT after downstaging showed 10-year post-LT survival and recurrence rates of 52.1% and 20.6%, respectively, for patients whose disease was downstaged; this compares to 61.5% and 13.3% for those consistently within the Milan criteria. Recently, the development of effective systemic treatments for HCC, such as immuno-oncologic agents, has provided additional opportunities for downstaging. Numerous clinical trials are exploring a multidisciplinary approach (MDA) combining LRT and systemic therapy. Although concrete evidence of the superiority of MDA for HCC downstaging is lacking, some retrospective studies and phase I and II trials have shown promising results regarding the efficacy and safety of MDA for this purpose. In this review, we will also discuss the future of MDA protocols in downstaging for improved clinical outcomes.
Citations
Citations to this article as recorded by
Effectiveness of Downstaging Advanced Hepatocellular Carcinoma for Liver Transplantation: Insights from a Decade of Single-Center Experience Erin M. Duggan, Nishtha Singh, Joanna K. Weeks, Adam Talenfeld, Benjamin May, Resmi Charalel, Ian Dinmore, Sarah Stucky, Tea Binder, Alexander J. Berman, Yana Glemaud, Arush Anand, Anthony Choi, Rebecca Craig-Schapiro, Dustin Carpenter, Benjamin Samstein, Digestive Disease Interventions.2026;[Epub] CrossRef
Transarterial Chemoembolization and Immunotherapy: Another Good Marriage? Landon L. Chan, Stephen L. Chan Journal of Clinical Oncology.2026; 44(11): 949. CrossRef
Low Tumor Burden Predicts Benefit from Transarterial Treatment in Hepatocellular Carcinoma with Extrahepatic Metastasis: A Nationwide Cohort Study Jaejun Lee, Hyun Yang, Keungmo Yang, Ji Won Han, Pil Soo Sung, Jeong Won Jang, Si Hyun Bae Liver Cancer.2026; : 1. CrossRef
Expanding the path to cure - a narrative review on optimizing multimodality sequencing in HCC Howard J. Lim, Arndt Vogel, Emma M. Dunne, Mayur Brahmania, Vincent C. Tam, Robert J. Abraham, Jennifer J. Knox, Jason K. Wong, Prosanto Chaudhury, Ravi Ramjeesingh, Peter T.W. Kim, Ilidio Martins, Leandro C. Leite, David Valenti, Gonzalo Sapisochin, Davi Cancer Treatment Reviews.2026; 149: 103194. CrossRef
Outcomes of living donor liver transplantation in elderly Egyptian patients: a retrospective study Ahmed Abdelrafee, Mohamed Abdelwahab, Amr Sanad, Ahmed Shehta, Mohamed Eldesoky, Mahmoud A. Ali, Mohamed A. Elmorshedi, Adel Ali Hassan, Waleed M. R. Elsarraf Langenbeck's Archives of Surgery.2026;[Epub] CrossRef
A concise review of updated global guidelines for the management of hepatocellular carcinoma: 2017-2024 Hyunjae Shin, Su Jong Yu Journal of Liver Cancer.2025; 25(1): 19. CrossRef
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment Stephen Lam Chan, Hui-Chuan Sun, Yang Xu, Hongmei Zeng, Hashem B El-Serag, Jeong Min Lee, Myron E Schwartz, Richard S Finn, Jinsil Seong, Xin Wei Wang, Valérie Paradis, Ghassan K Abou-Alfa, Lorenza Rimassa, Jia-Horng Kao, Bo-Heng Zhang, Josep M Llovet, Jo The Lancet.2025; 406(10504): 731. CrossRef
Liver Transplantation for Hepatocellular Carcinoma: A Comprehensive Review Seok-Hwan Kim Convergence Hepatology.2025; 1(1): 24. CrossRef
Radioembolization of primary liver tumors for patients with pre-existing ascites: beyond Child-Pugh score Fayez J. Jabboure, Joshua A. Marlow, Wyatt D. Reed, Naganathan B. Mani, Nassir Rostambeigi Abdominal Radiology.2025; 51(7): 3418. CrossRef